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Objectives: Phenylketonuria (PKU) is an orphan disease with incidence rate 1:5000 
in Egypt. Cost-effectiveness of Sapropterin versus Phenylalanine (PHE) free diet in 
PKU patients from the insurer perspective was evaluated over a time horizon of 10 
years. MethOds: A cohort Markov chain model with six health states: healthy, mild 
PKU, controlled mild PKU, classical PKU, controlled classical PKU and death was 
identified based on the process of the disease. The length of a cycle was set at one 
year. The transition probabilities were derived from updated, previously published 
studies in Egyptian patients with PKU. Relative risk of Sapropterin and utilities were 
derived using international published sources. Direct Medical costs were obtained 
from the Ministry of Health mandatory Tarrif in Egypt. All costs and effects were 
discounted at 3.5% annually. All costs were reported in Egyptian pounds of the 
financial year 2013. Deterministic sensitivity analysis was conducted. Results: 
Total costs for Sapropterin and PHE free diet were 304.1687 EGP and 188.6498 EGP 
respectively. QALYs for Sapropterin and PHE free diet were 0.00566 and 0.00547 
respectively. The incremental cost-effectiveness ratio (ICER) for Sapropterin versus 
PHE free diet was 602,933 EGP/QALY. Sapropterin is not cost effective because it is 
more than 3 times GDP/capita in Egypt (57,566 EGP). The ICER was most sensitive to 
the utility of the states ‘classical PKU’ and ‘controlled classical PKU’. cOnclusiOns: 
World Health Organization recommends that interventions that cost more than 3 
times GDP/capita for one Disability Adjusted Life Year (DALY) avoided should not be 
reimbursed. Despite the difference between DALY and QALY, one can assume they 
are similar to be able to put a value on the outcome. Sapropterin doesn’t represent 
a good value for money compared to PHE free diet in the Egyptian PKU patients.
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Objectives: LighterLife Total (LLT) is a weight loss programme for the obese (BMI 
≥ 30kg/m2) combining a very low calorie diet (VLCD) with weekly support groups 
for behaviour modification. This study evaluated the cost-effectiveness of LLT com-
pared with dietary and surgical interventions. This is the first study assessing the 
cost-effectiveness of a VLCD. MethOds: A cohort model was developed to assess 
the reduction in BMI in the first 12 months following intervention with LLT, gastric 
banding, gastric bypass, Weight Watchers, Counterweight, Slimming World and no 
treatment, and the subsequent yearly BMI increase. Published all cause-mortality was 
applied by age and BMI. Co-morbidity prevalence (diabetes, colorectal cancer, CHD) 
was applied by BMI. Costs were applied for each intervention and for co-morbidities, 
from a UK health care perspective. Utilities were calculated by BMI with an additional 
decrement for co-morbidities. A 10 year time horizon was used. Analyses were run for 
two subgroups: BMI 30-40 in and BMI > 40. Results: BMI 30-40: compared against no 
treatment, Counterweight, Weight Watchers and Slimming World, LLT was associated 
with higher costs, but also greater QALYs and was cost-effective against all, with incre-
mental cost-effectiveness ratios of £14,937, £16,004, £16,182, and £19,840, respectively. 
BMI > 40: compared against no treatment LLT incurred higher costs, but also greater 
QALYs and was cost-effective (ICER = £5,349). LLT was less effective than banding and 
bypass. The budget impact of uptake of LLT across the UK was assessed for both BMI 
30-40 and BMI > 40 groups. cOnclusiOns: BMI 30-40: LLT was more costly than 
dietary interventions, but lead to increased QALYs and was estimated to be cost-effec-
tive. BMI > 40: LLT resulted in a lower initial BMI reduction than gastric banding and 
bypass. LLT was estimated to be cost-effective against no treatment in both groups.
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Objectives: In Italy, within the legal mandate to pursue national self-sufficiency 
of secondary blood products, the Regions are starting to organize trade to off-
set need/availability unbalances. Therefore the determination of the full cost to 
the Regions of plasma collection and handling is needed. MethOds: Plasma 
is obtained from voluntary, non-remunerated donors either from full blood or 
from apheresis, and is collected either directly in facilities of the Regional Health 
Services, or indirectly through the net of donors’ associations before being deliv-
ered to the transformation industry for processing. Amount and costs of materi-
als and activities needed for collecting, producing, validating, and distributing 
plasma were obtained from the transfusional medicine department of the Verona 
province, Veneto Region. Attributable overhead expenses are assumed at 15% of 
direct cost. When plasma is collected as part of the whole blood or from multi-
component apheresis, common costs are attributed basing on the commercial 
value of single components, taken as proxy of the willingness-to-pay for them. 
In an alternative scenario, only product-specific costs are attributed to plasma 
recovered from whole blood donations, for which the driving need is the supply 
of red blood cells. Results: Total cost per liter of plasma sent for processing 
is estimated in 114 and 286 euros, respectively, for collection from whole blood 
and apheresis. Given the current mix of plasma origin, the weighed mean cost 
of plasma to the Regions before processing charges is estimated in 157 € . When 
plasma recovered from whole blood donations is considered by-product, its cost 
per liter sent to industry is estimated in 27 € , and the corresponding weighed 
mean cost in 92 € . cOnclusiOns: The Italian donor-based system, in addition to 
Objectives: To assess cost-effectiveness of PXF, used in combination with G-CSF 
versus standard mobilization options used alone, to enhance mobilization of haema-
topoietic stem cells to the peripheral blood for collection and subsequent autologous 
transplantation (auto-HCT). Target population, as defined by Polish opinion leaders, 
are patients with NHL/HL or MM whose cells mobilize poorly, i.e. predicted poor 
mobilizers (peripheral blood CD34+ cell count < 10/mL) and proven poor mobilizers 
(failure of previous mobilizations). MethOds: PXF is an add-on therapy to currently 
reimbursed standard mobilization (SM) options: G-CSF or chemotherapy plus G-CSF. 
Two scenarios were compared: with and without PXF. Analysis was performed using 
a Markov decision model, developed in TreeAge Pro 2013. A probabilistic (Monte Carlo 
simulation) model with time-dependent transition probabilities included initial 
cycle, during which the individual undergoes mobilization and auto-HCT if cell 
collection is successful, and four mutually exclusive health states: progression-free 
survival (remission and durable remission – lymphomas only), further treatment 
after progression, palliative treatment/observation and death. A one-year Markov 
cycle length was used with half-cycle correction. Baseline cohort characteristics, 
disease progression and utility estimates were obtained from systematic literature 
review and questionnaire study among Polish clinical practitioners. The analysis 
was conducted from the Polish public payer, patients, and societal perspective, over 
a lifetime horizon. Discount rates were 5% (costs) and 3.5% (outcomes). Results: 
The mean QALY gain were 7,378 (PXF) and 6,452 (SM). The mean costs were 188,404 
PLN (€ 45,019) (PXF) and 157,073 PLN (€ 37,532) (SM). Base-case incremental cost-util-
ity ratio (ICUR) in NHL/HL/MM population was 33,821 PLN/QALY (€ 8,082). Probability 
of PXF being cost-effective in Poland when compared to SM is 99,8% (current thresh-
old of 105,801 PLN/QALY (€ 25,281)). cOnclusiOns: Based on accepted cost/QALY 
threshold values in the Polish settings, PXF was proved to be cost-effective option 
for NHL/HL/MM patients with poor response to SM regimens.
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Objectives: To estimate the cost-utility of BEL treatment of patients with SLE as an 
add-on therapy to intensive standard of care (SOC) vs. SOC in Poland. MethOds: 
The general population considered in the analysis were patients with SLE with sig-
nificant disease activity, who met criteria of SLE diagnosis and were ineffectively 
treated with SOC. CUA was performed from the public payer perspective. The lifetime 
horizon was assumed. The decision model was developed in MS Excel and adjusted to 
Polish conditions. The calculations were performed using Monte Carlo microsimula-
tion. The model included data from international clinical studies and Polish data on 
costs and resource utilization. Direct medical costs were included: costs of drugs, 
administration, diagnostic, monitoring and costs related to disease activity. Results were 
calculated for two patients populations: target population 1 (TP1) - patients with 
positive anti-dsDNA, low complement and ≥ 10 scores in SELENA-SLEDAI scale and 
target population 2 (TP2) - patients with positive anti-dsDNA, low complement, ≥ 6 
scores in SELENA-SLEDAI scale and necessity of corticosteroids use. Results: CUA 
results showed that BEL compared to SOC is more costly however, also more effective 
therapy. The ICUR was 113,986 PLN/QALY and 108,744 PLN/QALY, respectively for TP1 
and TP2. Obtained results are placed slightly above the Polish acceptability threshold. 
Additional health effects related to BEL treatment instead of SOC were noticed both 
in LYG and QALY (0.432 and 0.4 LYG; 0.322 and 0.294 QALY, respectively for TP1 and 
TP2). Moreover, the model suggests lower frequency of cardiovascular events, and also 
pulmonary and renal complications in BEL arm. cOnclusiOns: Since there is cur-
rently no effective treatment option of SLE in Poland, reimbursement of belimumab 
will give patients an access to a safe and effective therapy, which allows them to 
return to active life and career and also to improve their quality of life.
PSY44
CoSt-utilitY analYSiS of DEfEraSirox for thE trEatmEnt of iron 
ovErloaD DuE to frEquEnt blooD tranSfuSionS in thE ChilDrEn anD 
aDolESCEntS
Walczak J.1, Sołtys E.1, Obrzut G.1, Laczewski T.2
1Arcana Institute, Cracow, Poland, 2Novartis Poland Sp. z o.o., Warsaw, Poland
Objectives: To estimate the cost-utility of deferasirox (DSX) treatment of iron over-
load due to frequent blood transfusions in children and adolescents in Polish condi-
tions. MethOds: Clinical effectiveness data were taken from previously performed 
systematic review of deferasirox for the treatment of pediatric patients (age ≤ 18 
years) with iron overload due to frequent blood transfusions. The way of administra-
tion of chelation therapy (parenteral vs. oral) significantly affects patients’ function-
ality and quality of life. Therefore it was decided to perform a cost-utility analysis. 
Analogous to other economic studies, it was assumed that patient survival was the 
same for both compared interventions: deferasirox and deferoxamine (DFO). In the 
analysis a simple decision model was developed. The calculations were performed 
using Monte Carlo microsimulation technique (100,000 trials). Only direct medical 
costs were included in the analysis: costs of drugs and their administration, costs 
of monitoring and costs of blood transfusions. The time horizon of the analysis was 
one-year period. Two perspectives were considered: a public payer (National Health 
Fund, NHF) and the patient and NHF perspective. The measure of effects was QALY 
(quality adjusted life years). Results: The results showed that DSX compared to 
current standard treatment of iron overload due to frequent blood transfusions 
(DFO) in the children and adolescents is more costly however also more effective 
therapy from both considered perspectives. The ICUR (incremental cost-utility ratio) 
of replacing DFO by DSX was 26,180 PN/QALY from NHF perspective. The results from 
both patient and NHF perspective was similar. cOnclusiOns: With reference to 
the acceptability threshold in Poland the oral chelation therapy in the population 
of children and adolescents with iron overload due to frequent blood transfusions 
with deferasirox is cost effective intervention when compared with deferoxamine.
